430 related articles for article (PubMed ID: 33319245)
1. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Lu J; Zhang Y; Wu C; Chu C; Liu Z; Cao Y
Jpn J Clin Oncol; 2021 Mar; 51(3):424-433. PubMed ID: 33319245
[TBL] [Abstract][Full Text] [Related]
2. The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer.
Liu Z; Ye Y; Li X; Guo S; Jiang L; Dong P; Li Y; Shi Y; Fan W; Cao Y; Yao K; Qin Z; Han H; Zhou F; Liu Z
World J Urol; 2018 Aug; 36(8):1191-1200. PubMed ID: 29459997
[TBL] [Abstract][Full Text] [Related]
3. Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
Wang T; Niu X; Zhong B
Jpn J Clin Oncol; 2022 May; 52(6):642-649. PubMed ID: 35348732
[TBL] [Abstract][Full Text] [Related]
4. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
[TBL] [Abstract][Full Text] [Related]
5. A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.
Yang GL; Zhang LH; Liu Q; Wang ZL; Duan XH; Huang YR; Bo JJ
Urol Oncol; 2017 Feb; 35(2):38.e9-38.e15. PubMed ID: 28040419
[TBL] [Abstract][Full Text] [Related]
6. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
Huang B; Wang H; Lin H; Yao Z; Zheng J; Fan W; Qiu S; Chen L; Chen J
J Cancer Res Clin Oncol; 2019 Feb; 145(2):487-494. PubMed ID: 30539282
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM
Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794
[TBL] [Abstract][Full Text] [Related]
10. The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells.
Rose M; Noetzel E; Kistermann J; Eschenbruch J; Rushrush S; Gan L; Knüchel R; Gaisa NT; Dahl E
Cells; 2021 Apr; 10(5):. PubMed ID: 33924987
[TBL] [Abstract][Full Text] [Related]
11. Commentary on "A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.".
Yang GL; Zhang LH; Liu Q; Wang ZL; Duan XH; Huang YR; Bo JJ
Urol Oncol; 2018 Jul; 36(7):346-347. PubMed ID: 29859729
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.
Huang B; Zheng J; Yao Z; Fan W; Qiu S; Chen L; Chen J
World J Urol; 2019 May; 37(5):823-829. PubMed ID: 30191393
[TBL] [Abstract][Full Text] [Related]
13. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Huang B; Huang G; Li W; Chen L; Mao X; Chen J
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
Matsumura N; Nakamura Y; Kohjimoto Y; Nishizawa S; Kikkawa K; Iba A; Kodama Y; Hara I
Int J Urol; 2017 Mar; 24(3):230-235. PubMed ID: 28066957
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Rose TL; Harrison MR; Deal AM; Ramalingam S; Whang YE; Brower B; Dunn M; Osterman CK; Heiling HM; Bjurlin MA; Smith AB; Nielsen ME; Tan HJ; Wallen E; Woods ME; George D; Zhang T; Drier A; Kim WY; Milowsky MI
J Clin Oncol; 2021 Oct; 39(28):3140-3148. PubMed ID: 34428076
[TBL] [Abstract][Full Text] [Related]
18. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
[TBL] [Abstract][Full Text] [Related]
19. D2-40/podoplanin expression in cancer stroma by immunohistochemical staining is associated with poor prognosis in bladder cancer patients after radical cystectomy.
Okajima E; Tomizawa M; Shimada K; Negishi T; Nishiyama N; Kitamura H
Urol Oncol; 2020 Oct; 38(10):797.e7-797.e13. PubMed ID: 32576528
[TBL] [Abstract][Full Text] [Related]
20. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]